Coherus Oncology, Inc. (CHRS): Depreciation & Amortization
$3.92M
Year ended 2025-12-31
$3.60M
Trailing 12 months to 2026-06-30
+2.0%
3-year compound annual growth
+6.3%
5-year compound annual growth
+7.7%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.92M | -25.6% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $5.28M | +39.2% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $3.79M | +2.5% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $3.70M | +7.1% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $3.45M | +19.6% | 2024-03-15, From 2021-01-01 |
| 2020-12-31 | $2.89M | -11.4% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $3.26M | +0.7% | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | $3.23M | -4.8% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $3.40M | +13.4% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $3.00M | +60.3% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $1.87M | +177.3% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $674.0K | +66.8% | 2017-03-14, From 2014-01-01 |
| 2013-12-31 | $404.0K | +82.8% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $221.0K | n/a | 2015-03-23, From 2012-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $3.92M | -25.6% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $1.38M | -16.4% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $268.0K | -11.8% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $12.54M | -2.2% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $2.99M | +9.8% |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $1.64M | -33.4% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $1.28M | +60.4% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $2.90M | -29.3% |
| Alector, Inc. (ALEC) | 2025-12-31 | $5.72M | +5.8% |
Compare CHRS, TECX, LXEO, MGTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗